Could REGEN-COV’s New US FDA Emergency Use Authorization Revive COVID-19 Prophylaxis Pipeline?
Regeneron’s neutralizing antibody cocktail earned the first post-exposure prophylaxis EUA for COVID-19, but the new use and dosing improvements need to overcome slow uptake under the original authorization for the COVID-19 treatment and the poisoned environment left by hydroxychloroquine controversies.
You may also be interested in...
The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”
The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.
Coronavirus Update: Storage Boost For Pfizer/BioNTech, More Positive Data For Regeneron Antibody Cocktail
The approved fridge storage time for Pfizer and BioNTech's Comirnaty has been extended to a month, Regeneron's scores with low-dose REGEN-COV, an early win for GSK and CureVac's next-generation mRNA vaccine and more orders of the AstraZeneca vaccine benefits Oxford Biomedica's bank balance.